In contrast, another PD-L1 inhibitor avelumab, which was administered before, during, and after the chemoradiotherapy phase in the JAVELIN Head and Neck 100 study [25], did not improve either PFS or OS compared with the placebo for locally advanced squamous cell carcinoma of the head and neck. This evidence concerns the gene CD274 and squamous cell carcinoma.